Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valentina D'Amato

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Annals of Translational Medicine|January 7, 2016
Integr(at)in(g) EGFR therapy in HNSCCValentina D'Amato, Roberta Rosa, Roberto Bianco
Expert Opinion on Drug Discovery|October 5, 2016
Approaches for targeting cancer stem cells drug resistanceRoberta Rosa, Valentina D'Amato, Sabino De Placido, et al.
Cancer Treatment Reviews|August 16, 2015
Mechanisms of lapatinib resistance in HER2-driven breast cancerValentina D'Amato, Lucia Raimondo, Luigi Formisano, et al.
Critical Reviews in Oncology/Hematology|February 5, 2020
Mechanisms of resistance to mTOR inhibitorsLuigi Formisano, Fabiana Napolitano, Roberta Rosa, et al.
Scientific Reports|February 16, 2018
Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probeHadis Honarvar, Enrica Calce, Nunzianna Doti, et al.
The Journal of Biological Chemistry|May 25, 2010
Reactive oxygen species, Ki-Ras, and mitochondrial superoxide dismutase cooperate in nerve growth factor-induced differentiation of PC12 cellsSilvana Cassano, Savina Agnese, Valentina D'Amato, et al.
Breast Cancer Research : BCR|June 3, 2014
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer modelsLuigi Formisano, Lucia Nappi, Roberta Rosa, et al.
Breast Cancer Research : BCR|December 22, 2025
Retraction Note: Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer modelsLuigi Formisano, Lucia Nappi, Roberta Rosa, et al.
Oncotarget|September 2, 2015
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational statusLuigi Formisano, Valentina D'Amato, Alberto Servetto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2012
Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer modelsRoberta Rosa, Roberta Marciano, Umberto Malapelle, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Annals of Translational Medicine|January 7, 2016
Integr(at)in(g) EGFR therapy in HNSCCValentina D'Amato, Roberta Rosa, Roberto Bianco
Expert Opinion on Drug Discovery|October 5, 2016
Approaches for targeting cancer stem cells drug resistanceRoberta Rosa, Valentina D'Amato, Sabino De Placido, et al.
Cancer Treatment Reviews|August 16, 2015
Mechanisms of lapatinib resistance in HER2-driven breast cancerValentina D'Amato, Lucia Raimondo, Luigi Formisano, et al.
Critical Reviews in Oncology/Hematology|February 5, 2020
Mechanisms of resistance to mTOR inhibitorsLuigi Formisano, Fabiana Napolitano, Roberta Rosa, et al.
Scientific Reports|February 16, 2018
Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probeHadis Honarvar, Enrica Calce, Nunzianna Doti, et al.
The Journal of Biological Chemistry|May 25, 2010
Reactive oxygen species, Ki-Ras, and mitochondrial superoxide dismutase cooperate in nerve growth factor-induced differentiation of PC12 cellsSilvana Cassano, Savina Agnese, Valentina D'Amato, et al.
Breast Cancer Research : BCR|June 3, 2014
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer modelsLuigi Formisano, Lucia Nappi, Roberta Rosa, et al.
Breast Cancer Research : BCR|December 22, 2025
Retraction Note: Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer modelsLuigi Formisano, Lucia Nappi, Roberta Rosa, et al.
Oncotarget|September 2, 2015
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational statusLuigi Formisano, Valentina D'Amato, Alberto Servetto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2012
Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer modelsRoberta Rosa, Roberta Marciano, Umberto Malapelle, et al.
Pageof 2